Estrogen insensitivity syndrome
Estrogen Insensitivity Syndrome

Estrogen Insensitivity Syndrome is a rare genetic condition characterized by the body's inability to respond to estrogen, a key hormone in the development and regulation of the female reproductive system and secondary sexual characteristics. This condition is caused by mutations in the estrogen receptor gene, leading to a non-functional receptor that cannot bind estrogen effectively.
Pathophysiology
The syndrome results from mutations in the ESR1 gene, which encodes the estrogen receptor alpha. This receptor is crucial for mediating the effects of estrogen in various tissues, including the breast, uterus, and bone. In individuals with estrogen insensitivity syndrome, the receptor is unable to bind estrogen, leading to a lack of estrogenic effects in the body.
Clinical Presentation
Individuals with estrogen insensitivity syndrome typically present with symptoms of estrogen deficiency despite normal or elevated levels of circulating estrogen. In females, this may include:
- Lack of breast development
- Primary amenorrhea
- Infertility
- Osteoporosis
In males, the condition may present with:
- Lack of pubertal development
- Gynecomastia
- Infertility
Diagnosis
Diagnosis of estrogen insensitivity syndrome involves a combination of clinical evaluation, hormonal assays, and genetic testing. Elevated levels of circulating estrogen with a lack of expected physiological response suggest the condition. Genetic testing can confirm mutations in the ESR1 gene.
Management
Management of estrogen insensitivity syndrome is primarily supportive and symptomatic. Hormone replacement therapy may be considered, although its effectiveness is limited due to the receptor's insensitivity. Management of osteoporosis and other complications is crucial.
Related Pages
| Genetic disorders relating to deficiencies of transcription factor or coregulators | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian